Nivolumab (Opdivo)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: PD-1 receptor antibody. Nivolumab is an IgG4 kappa human monoclonal antibody which binds to the PD-1 (programmed death receptor-1) receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Normally, PD-L1 and PD-L2 binding to the PD-1 receptor on T cells inhibits T-cell proliferation and cytokine production, which can impede immune system surveillance of tumors. By interfering with the binding of PD-L1 and PD-L2 to the PD-1 receptor, nivolumab can cause upregulation of the anti-tumor immune response.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code names: BMS-936558, MDX-1106, ONO-4538
  • Brand name: Opdivo

References

  1. 1.0 1.1 1.2 Nivolumab (Opdivo) package insert
  2. Nivolumab (Opdivo) package insert (locally hosted backup)
  3. Opdivo manufacturer's website
  4. Nivolumab (Opdivo) patient drug information (Chemocare)
  5. Nivolumab (Opdivo) patient drug information (UpToDate)